Dr David Sheridan
Profiles

Dr David Sheridan

Associate Professor (Senior Lecturer) & Honorary Consultant in Hepatology

Biomedical Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of Medicine and De

Role

Dr Sheridan is Associate Professor in Hepatology at the Institute of Translational & Stratified Medicine, Plymouth University Peninsula Schools of Medicine & Dentistry and Honorary consultant hepatologist at the South West Liver Unit, Derriford Hospital.  Research interests are chronic hepatitis C virus, metabolism and non-alcoholic fatty liver disease.

Qualifications

Qualifications:

BSc Immunology & Cell Pathology, University College London 1997
MB BS Royal Free & University College London Medical School 2000 (with distinction)
MRCP(UK) 2003
PhD Newcatle University 2010

Previous posts:

PRHO Whittington Hospital, London 2000-2001
SHO University Hospitals Leicester medical rotation 2001-2004
Specialist Registrar Gastroenterology and Hepatology, Northern Deanery 2004 - 2014
MRC Clinical Research Fellow, Newcastle University 2007 - 2010
NIHR Academic Clinical Lecturer Newcastle University 2011-2014
Sub-specialty NTN in Hepatology and Liver Transplantation, Freeman Hospital, Newcastle upon Tyne 2012-13
Visiting Scholar, Storr liver Unit, Westmead Millenium Institute, University of Sydney 2013-14

Professional membership

GMC 4718282
Royal College of Physicians of London
British Society for the Study of the Liver  (BASL)
European Society for the study of the Liver (EASL)

Teaching interests

Post Graduate Certificate in Clinical Education, 2015. Plymouth University

Research interests

Hepatitis C Virus
Lipid metabolism
Non-alcoholic fatty liver disease

Mitochondrial bioenergetics
Clinical Trials

Key publications are highlighted

Journals
Articles
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S & Newsome PN 2017 'Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey' Frontline Gastroenterology flgastro-2017-100806-flgastro-2017-100806 , DOI PEARL
Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME 2017 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis , DOI PEARL
Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ & Neely RD 2017 'Hepatitis C virus and atherosclerosis: A legacy after virologic cure?' Clinics and Research in Hepatology and Gastroenterology 41, (1) 25-30 , DOI
Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D & Grønbæk H 2017 'IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis' Nature Genetics 49, (5) 795-800 , DOI PEARL
Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME 2017 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 , DOI PEARL
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC & Odin JA 2017 'Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study' Lancet Gastroenterology & Hepatology Author Site , DOI PEARL
Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA & Najim MAM 2016 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes' Hepatology 64, (1) 34-46 , DOI PEARL
Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D & Abate ML 2016 'FibroGENE: A gene-based model for staging liver fibrosis' Journal of Hepatology 64, (2) 390-398 , DOI
Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ & Lloyd AR 2016 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection' Liver International , DOI PEARL
Khaled Thabet,, Anastasia Asimakopoulos, Maryam Shojaei, Manuel Romero-Gomez, Alessandra Mangia, William L. Irving, Thomas Berg, Gregory J. Dore, Henning Grønbæk & Sheridan DA 2016 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C' Nature Communications , DOI PEARL
Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HLK, Irving WL, Sheridan D & Abate ML 2015 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease' Nature Communications 6, 6422-6422 , DOI PEARL
Bridge SH, Sheridan DA, Felmlee DJ, Crossey MME, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J & Thomas HC 2015 'PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism' Journal of Hepatology 62, (4) 763-770 , DOI PEARL
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF 2014 'Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency' Metabolic Brain Disease 29, (3) 625-634 , DOI
Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W & Bugianesi E 2014 'IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection' J Hepatol 61, (2) 235-241 Author Site , DOI
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick FI, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF 2014 'Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial' Liver International 34, (5) 737-747 , DOI
Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ & Irving WL 2013 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection' Genes and Immunity 14, (5) 286-290 , DOI
Sheridan DA, Neely RDG & Bassendine MF 2013 'Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)' Clinics and Research in Hepatology and Gastroenterology 37, (1) 10-16 , DOI
Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ & Neely RDG 2013 'Lipids and HCV' Seminars in Immunopathology 35, (1) 87-100 , DOI
Sheridan DA, Bridge SH, Felmlee DJ, Crossey MME, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RDG & Bassendine MF 2012 'Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity' Journal of Hepatology 57, (1) 32-38 , DOI
Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL & Neely RDG 2011 'HCV and the hepatic lipid pathway as a potential treatment target' Journal of Hepatology 55, (6) 1428-1440 , DOI
Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate M, Spengler U, Bassendine M, Matthews G & Irving WL 2011 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort' Genome Medicine 3, (8) 57-57 , DOI
Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M & Dore GJ 2011 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study' PLoS Med 8, (9) Author Site , DOI
Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, Neely RDG, Toms GL & Bassendine MF 2011 'Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection' Gut 60, (5) 680-687 , DOI
Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL & Neely RDG 2010 'Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles' Gastroenterology 139, (5) 1774-1783.e6 , DOI
SHERIDAN DA, PRICE DA, SCHMID ML, TOMS GL, DONALDSON P, NEELY D & BASSENDINE MF 2009 'Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin' Alimentary Pharmacology & Therapeutics 29, (12) 1282-1290 , DOI
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ & Powell E 2009 'IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy' Nature Genetics 41, (10) 1100-1104 , DOI
Letters
Francis J, Sheridan D, Samanta A & Nichol FE 2005 'Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume' Ann Rheum Dis 64, (5) 787-788 Author Site , DOI

Other academic activities

Editorial Board membership: 

2016-present: Scientific Reports (Nature Publishing Group)